United States:
Biolojic Design Ltd. Research Collaboration And License Agreement With Eli Lilly
10 March 2021
Pearl Cohen Zedek Latzer Baratz
To print this article, all you need is to be registered or login on Mondaq.com.
Pearl Cohen advises Biolojic Design Ltd. on intellectual
property matters on the research collaboration and license
agreement with Eli Lilly that will leverage Biolojic's AI-based
multibody platform to discover and develop a potential novel
antibody-based therapy for the treatment of diabetes.
Mark Cohen, Senior Partner and Chair of the
Life Sciences Practice Group represents Biolojic Design, Ltd. in
its intellectual property and patent prosecution matters.
See full article here.
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
POPULAR ARTICLES ON: Intellectual Property from United States
Are Your NDAs Up To Date?
Wolf, Greenfield & Sacks, P.C.
Nondisclosure agreements (NDAs) can be used to protect companies' confi dential and trade secret information. But you should resist the urge to have a vendor...
Legal Implications Of New York Times vs. OpenAI
BoyarMiller
The New York Times recently filed a landmark lawsuit against OpenAI and Microsoft, accusing them of copyright infringement in the training of the chatbot ChatGPT which launched just over a year ago.
